Global Coronary Stents Market is forecasted to grow at a CAGR of 3.05% during 2016-2021F, on account of rising incidences of cardiovascular diseases globally leading to growing number of stent procedures.
Rising development of bioresorbable stents combined with the growing awareness towards cardiovascular risks in developing countries has resulted in the growth of coronary stents market. Cardiovascular diseases are witnessing growth on account of the rise in the lifestyle related diseases including obesity, diabetes, hypertension etc.
Among the types of coronary stents, market is expected to be driven by bioresorbable stents, mainly in the polylactic acid material. However, drug eluting stents will continue to generate major revenue while bare metal stents will further continue to decline.
While developed regions will continue to dominate the market in terms of revenue, emerging nations are expected to respond to the market optimistically due to the developing healthcare infrastructure and rising focus on healthcare among the growing middle class population.
Scope of the Report
The report provides Segmentation by Stent Type:
- Bare Metal stents
- Drug-Eluting Stents
- Bioresorbable Stents
Key Topics Covered:
1. Research Methodology
2. Executive Summary
3. Strategic Recommendations
3.1. Bioresorbable Stents as the Future Market
3.2. Focus on Lowering of ASP in Coronary Stents
3.3. Opportunities in APAC Region
4. Global Coronary Stents Market: An Analysis
4.1. Product Overview
4.2. Global Coronary Stents Market
4.3. Global Coronary Stent Market, By Segments
4.4. Global Bare Metal Stents, By Value
4.5. Global Drug Eluting Stents, By Value
4.6. Global Bioresorbable Stents Market, By Segments
4.7. Global Coronary Stent Market, By Region
4.8. Coronary Stents: Pipeline Analysis
5. North America Coronary Stent Market: An Analysis
6. Europe Coronary Stent Market: An Analysis
7. APAC Coronary Stent Market: An Analysis
8. ROW Coronary Stent Market: An Analysis
9. Market Dynamics
10. Pricing Structure
11. Policy and Regulatory Landscape
12. M&A and Licensing Route to Coronary Stent Market